The Global Veterinary Pharmacovigilance Market was valued at USD 804.49 million in 2023 and is projected to expand at a CAGR of 13.6% from 2024 to 2032, reaching USD 2534.69 million by 2032. This rapid expansion is driven by increasing veterinary drug approvals, growing awareness about veterinary pharmacovigilance reporting, stricter regulatory compliance requirements, and public and private initiatives to ensure drug safety for animals.
The rising pet ownership, increasing demand for advanced veterinary medicines, and growing investments in pharmacovigilance technologies are further propelling market growth. The emphasis on adverse event monitoring, signal detection, and post-market surveillance of veterinary drugs has become paramount, leading to the adoption of pharmacovigilance software solutions and services. Furthermore, regulatory authorities worldwide are imposing stricter guidelines for veterinary drug approvals and pharmacovigilance inspections, ensuring the safety and efficacy of veterinary pharmaceuticals.
The integration of artificial intelligence (AI), data analytics, and machine learning (ML) in veterinary pharmacovigilance is playing a pivotal role in enhancing the accuracy and efficiency of adverse event monitoring. AI-powered pharmacovigilance software enables real-time detection and reporting of adverse drug reactions (ADRs) and medication errors, helping veterinary pharmaceutical companies comply with evolving regulations. For instance, in 2024, the World Health Organization (WHO) expanded its International Drug Monitoring Programme, reflecting a global commitment to strengthening pharmacovigilance systems. Similarly, the European Union (EU) has intensified its focus on continuous signal management to ensure the safety of veterinary medicinal products.
From a regional perspective, North America dominated the veterinary pharmacovigilance market in 2024, holding a 40.0% revenue share, primarily due to well-established veterinary healthcare infrastructure, stringent regulatory guidelines, and the presence of leading pharmacovigilance service providers. The Asia-Pacific region is expected to grow at the fastest CAGR of 15.4%, fueled by rising pet ownership, increasing government regulations on veterinary drug safety, and expanding veterinary healthcare investments in countries like China, India, and Japan.
Major Market Players Included in This Report:
• ArisGlobal
• Accenture
• Ennov
• Sarjen Systems Pvt. Ltd.
• Pharsafer Associates Limited
• Knoell
• Biologit
• Indivirtus
• Azierta Contract Science Support Consulting
• Oy Medfiles Ltd.
The Detailed Segments and Sub-Segment of the Market Are Explained Below:
By Solution:
• Software
• Services
By Type:
• In-house
• Contract Outsourcing
By Product:
• Biologics
• Anti-Infective
• Other Products
By Animal Type:
• Dogs
• Cats
• Other Animal Types
By Region:
North America
• U.S.
• Canada
• Mexico
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Thailand
• Rest of Asia Pacific
Latin America
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
• Rest of Middle East & Africa
Years Considered for the Study:
• Historical Year – 2022
• Base Year – 2023
• Forecast Period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years (2022-2032)
• Annualized Revenue and Regional-Level Analysis for each market segment
• Geographical Breakdown with country-level market evaluations
• Competitive Landscape Analysis with information on major market players
• Insights into Key Business Strategies, Growth Drivers, and Challenges
• Supply & Demand Side Analysis of the market
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook